(VIANEWS) – CEGEDIM (CGM.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| CEGEDIM (CGM.PA) | €21.45 | 2.54% | 4.5% |
| ESSILORLUXOTTICA (EL.PA) | €172.04 | 1.75% | 6.16% |
| EQUASENS (EQS.PA) | €84.50 | 1.47% | 28.59% |
| IBA (IBAB.BR) | €15.44 | 1.19% | 5.01% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. CEGEDIM (CGM.PA)
2.54% Forward Dividend Yield and 4.5% Return On Equity
Cegedim SA operates as a technology and services company in the field of digital data flow management for healthcare ecosystem and B2B, and business software publisher for healthcare and insurance professionals in France, other European countries, and internationally. It operates in two segments, Health Insurance, HR and e-Services; and Healthcare Professionals. The Health Insurance, HR and e-Services segment markets various products and services to insurance companies, mutual insurers, personal protection insurers, and insurance brokers, as well as engages in the interactions between these entities and healthcare professionals. This segment also provides solutions for hosting, HR and payroll management outsourcing, electronic data exchange, and data processing services. The Healthcare Professionals division sells management software, databases, and solutions to doctors, allied health professionals, pharmacists, and healthcare facilities. The company was incorporated in 1969 and is headquartered in Boulogne-Billancourt, France. Cegedim SA is a subsidiary of FCB SA.
Earnings Per Share
As for profitability, CEGEDIM has a trailing twelve months EPS of €1.
PE Ratio
CEGEDIM has a trailing twelve months price to earnings ratio of 21.45. Meaning, the purchaser of the share is investing €21.45 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.5%.
More news about CEGEDIM.
2. ESSILORLUXOTTICA (EL.PA)
1.75% Forward Dividend Yield and 6.16% Return On Equity
EssilorLuxottica Société anonyme engages in design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses in Europe, Middle East, Africa, Latin America, Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Crizal, Essilor, Eyezen, Stellest, Xperio, Optifog, Satisloh, Barberini, Shamir, Nikon, KODAK Lens, Oakley, OPTIFOG, Ray-Ban, Transitions, Vailux, and Xperio brands. It also provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Alain Mikli, Costa del Mar, Native Eyewear, Luxottica, Sferoflex, Heritage, Sensaya, Miki Ninn, DbyD, Unofficial and Seen, Arnette, Vogue Eyewear, Bolon, Molsion, and Ossé, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of physical stores or its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ESSILORLUXOTTICA has a trailing twelve months EPS of €4.83.
PE Ratio
ESSILORLUXOTTICA has a trailing twelve months price to earnings ratio of 35.62. Meaning, the purchaser of the share is investing €35.62 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.16%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.1%, now sitting on 24.49B for the twelve trailing months.
Moving Average
ESSILORLUXOTTICA’s worth is above its 50-day moving average of €168.07 and higher than its 200-day moving average of €164.43.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 22, 2023, the estimated forward annual dividend rate is 3.23 and the estimated forward annual dividend yield is 1.75%.
Yearly Top and Bottom Value
ESSILORLUXOTTICA’s stock is valued at €172.04 at 17:30 EST, below its 52-week high of €188.28 and way above its 52-week low of €132.70.
More news about ESSILORLUXOTTICA.
3. EQUASENS (EQS.PA)
1.47% Forward Dividend Yield and 28.59% Return On Equity
Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker solutions for pharmacists' business processes; and solutions for energizing the customer relationship with pharmacists comprising OffiTag, OffiTouch, OffiMédia, OffiConnect, automation systems, and customer loyalty programs. The company also provides My Pilot, an analytics and management tool; OffiLearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, Multimeds, Automeds, and OffiTéléconsult, as well as pharmaceutical record and shared medical record services. In addition, it offers a ULTIMATE, a system combining optimized pharmacy management and improved patient support; FARMACLICK, a protocol for communications between pharmacies and wholesalers-distributors; DIFARM, a solution for wholesalers-distributors; PHARE, a retail management tool; SOPHIA, a pharmacy management application; OffiMédia POS display; eNephro to enhance the care of chronic renal failure patients; and TPE Pilot, a web-based application that simplifies the management and sharing of patient education programs. Further, the company provides NOVIACARE; CARELIB Domicile; CARELIB EHPAD; KAPELSE solutions; TITAN solutions; ANTHADINE software and MOBISOINS mobile tool; MICROSOINS, an in-home nursing care solution; and LOGICLIC. Additionally, it offers AXIGATE solutions to manage the entire patient care pathway; CHORUS platform; medical telesecretarial services for healthcare professionals; and equipment lease financing solutions. The company was incorporated in 1996 and is based in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
Earnings Per Share
As for profitability, EQUASENS has a trailing twelve months EPS of €3.05.
PE Ratio
EQUASENS has a trailing twelve months price to earnings ratio of 27.7. Meaning, the purchaser of the share is investing €27.7 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.59%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EQUASENS’s stock is considered to be oversold (<=20).
More news about EQUASENS.
4. IBA (IBAB.BR)
1.19% Forward Dividend Yield and 5.01% Return On Equity
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
Earnings Per Share
As for profitability, IBA has a trailing twelve months EPS of €0.2.
PE Ratio
IBA has a trailing twelve months price to earnings ratio of 77.2. Meaning, the purchaser of the share is investing €77.2 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.01%.
Moving Average
IBA’s worth is under its 50-day moving average of €16.15 and below its 200-day moving average of €15.75.
Volume
Today’s last reported volume for IBA is 2493 which is 77.36% below its average volume of 11016.
Volatility
IBA’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.30%, a positive 0.30%, and a positive 1.16%.
IBA’s highest amplitude of average volatility was 0.98% (last week), 1.49% (last month), and 1.16% (last quarter).
More news about IBA.
